| Princeton University, AB | |
| Molecular Biology | |
| Columbia University, M.S. | |
| Health Policy | |
| Harvard Business School, M.B.A. |
Dr. Salehizadeh has 12 years of healthcare operating and investment experience. Prior to co-founding NaviMed Capital, he was a General Partner at Highland Capital Partners, where he focused on venture and growth stage healthcare investments.
Prior to joining Highland in 2003, Dr. Salehizadeh spent several years in marketing at Medtronic where he worked closely with Mr. Canann. Before Medtronic, Dr. Salehizadeh held a variety of senior management roles with HealthCentral, a venture-backed healthcare information technology company that went public in 1999. During his medical training, Dr. Salehizadeh conducted research in minimally invasive heart valves and left ventricular assist devices.
He is currently on the board of directors of Auris Surgical, BÂRRX Medical, Hyperion Therapeutics, OpGen and Predictive Biosciences, and has sourced or been actively involved in Highland’s investments in Baronova, Entourage Medical, Pharmaca Integrative Pharmacy, kyruus, AVEO Pharmaceuticals (IPO), and Conor Medsystems (IPO; acquired by Johnson & Johnson for $1.4 billion in 2007).
Dr. Salehizadeh holds an A.B. in Molecular Biology from Princeton University, an M.D. and Master’s in Science in Health Policy from Columbia University, and an M.B.A. from Harvard Business School. He is also a graduate of the Kauffman Fellows Program.
